Pharmacy Times April 25, 2025
A panelist discusses how combining therapies for EGFR-positive non–small cell lung cancer (NSCLC) increases both benefits (improved progression-free survival, response rates, and duration of response) and adverse effects, emphasizing that treatment selection should consider patient-specific factors like central nervous system (CNS) metastases, performance status, treatment aggressiveness preferences, and real-world limitations where patients often differ from clinical trial populations in terms of organ dysfunction, concomitant medications, and previous treatments.
Balancing Benefits and Risks in EGFR-Positive NSCLC: Clinical Considerations
Combination Therapy vs Monotherapy: Key Considerations
Benefit-Risk Assessment
- Combination therapies:
- Provide greater efficacy benefits (improved progress-free survival, response rates, duration of response)
- Consistently demonstrate more adverse effects when adding additional agents
- Overall survival data for newer combinations still maturing
- Adverse effect...
Today's Sponsors
Today's Sponsor